Conference
S98 Antacid therapy and disease progression in patients with idiopathic pulmonary fibrosis (IPF) under pirfenidone treatment
Abstract
On the basis of retrospective and post-hoc analyses the current IPF guideline suggests the use of anti-acid therapy (AAT, i.e., proton pump inhibitors and H2-blockers) as a treatment option in patients with IPF. While recent post-hoc analyses do not support a protective effect of AAT on IPF progression in patients receiving placebo, the impact of AAT on disease progression in patients treated with pirfenidone is unknown. Patients with IPF …
Authors
Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher T; Kolb M; Weycker D; Kirchgässler K
Volume
71
Publisher
BMJ
Publication Date
12 2016
DOI
10.1136/thoraxjnl-2016-209333.104
Conference proceedings
Thorax
Issue
Suppl 3
ISSN
0040-6376